[Edaily Starin Reporter KIM HYUNSIK ] Cravity members Allen and Wonjin shared their thoughts on leaving “Simply K-Pop.” (Photo courtesy of Starship Entertainment)(Photo courtesy of Starship Entertainment)
Alan and Wonjin concluded their run as hosts of Arirang TV’s music program “Simply K-Pop” with the broadcast on the 21st. They hosted the program for about four months, starting last April. On the final broadcast, they performed a special stage of “Divin” by their group, CRAVITY. On the 22nd, through their agency Starship Entertainment, Allen and Wonjin shared, “It feels like time has flown by—it seems like just yesterday we were recording our first episode, and now it’s already the final broadcast.” They added, “We were able to feel the fans’ love for K-pop even more closely, and we gained a lot of positive energy from watching the performances of many artists.” They continued, “We are so grateful to all the viewers who have watched us this whole time, as well as to ‘Lovity’ (the official fan club name) who cheered us on every week—both on-site and from afar,” and added, “We’ll work hard to continue bringing you great music and performances in the future.” Allen previously served as a host on Arirang TV’s K-pop talk show “After School Club.” Wonjin showcased her diverse charms through appearances on MBC’s “King of Mask Singer” and the YouTube series “Workdol.” Meanwhile, CRAVITY releases its original content series “CRAVITY Park” every Monday at 9 p.m. on its official YouTube channel.
Lisa Su, Chairwoman and CEO of AMD, concluded a meeting lasting over three hours with Jeon Young-hyun, President and CEO of SamsungElectronics and Vice Chairman in charge of the Device Solutions (DS) …
Epfeglenatide, developed by HanmiPharm, has received approval from the Ministry of Food and Drug Safety as the first domestically developed GLP-1-based obesity treatment. With this approval, Korea has…
A new domestically developed drug has emerged to compete in the obesity treatment market, which is currently dominated by global pharmaceutical companies. With HanmiPharm’s efeglenatide receiving mark…